Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1449106rdf:typepubmed:Citationlld:pubmed
pubmed-article:1449106lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0007137lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0460004lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C1264633lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0439590lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0439858lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0205187lld:lifeskim
pubmed-article:1449106lifeskim:mentionsumls-concept:C0521115lld:lifeskim
pubmed-article:1449106pubmed:issue6lld:pubmed
pubmed-article:1449106pubmed:dateCreated1992-12-30lld:pubmed
pubmed-article:1449106pubmed:abstractTextCisplatin (CDDP) and 5-fluorouracil (5-FU) have been used alone, in combination, and in various doses and sequences with radiation therapy in attempts to improve local control and survival of patients with advanced head and neck cancer. This study was undertaken to determine the toxicity and maximum tolerated dose of high-dose CDDP plus prolonged infusion 5-FU with concomitant conventional radiation therapy. Twenty-two patients with inoperable Stage III and IV squamous cell cancer were treated with CDDP (30 or 35 mg/m2 for 5 days every 4 weeks for three courses) and 5-FU (200 or 300 mg/m2 per day continuous i.v. infusion for 12 weeks) with concomitant conventional radiation therapy. This aggressive treatment regimen is accompanied by severe mucositis, myelosuppression, and chronic neuropathy. CDDP, 35 mg/m2/day x 5, and 200 mg/m2/day of 5-FU infused over 12 weeks were identified as potential doses for future Phase II studies.lld:pubmed
pubmed-article:1449106pubmed:languageenglld:pubmed
pubmed-article:1449106pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1449106pubmed:citationSubsetIMlld:pubmed
pubmed-article:1449106pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1449106pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1449106pubmed:statusMEDLINElld:pubmed
pubmed-article:1449106pubmed:monthDeclld:pubmed
pubmed-article:1449106pubmed:issn0277-3732lld:pubmed
pubmed-article:1449106pubmed:authorpubmed-author:SpencerS ASAlld:pubmed
pubmed-article:1449106pubmed:authorpubmed-author:MeredithR FRFlld:pubmed
pubmed-article:1449106pubmed:authorpubmed-author:SalterM MMMlld:pubmed
pubmed-article:1449106pubmed:authorpubmed-author:KimR YRYlld:pubmed
pubmed-article:1449106pubmed:authorpubmed-author:StephensSSlld:pubmed
pubmed-article:1449106pubmed:authorpubmed-author:WeppelmannBBlld:pubmed
pubmed-article:1449106pubmed:authorpubmed-author:WheelerR HRHlld:pubmed
pubmed-article:1449106pubmed:authorpubmed-author:PetersG EGElld:pubmed
pubmed-article:1449106pubmed:issnTypePrintlld:pubmed
pubmed-article:1449106pubmed:volume15lld:pubmed
pubmed-article:1449106pubmed:ownerNLMlld:pubmed
pubmed-article:1449106pubmed:authorsCompleteYlld:pubmed
pubmed-article:1449106pubmed:pagination461-3lld:pubmed
pubmed-article:1449106pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:meshHeadingpubmed-meshheading:1449106-...lld:pubmed
pubmed-article:1449106pubmed:year1992lld:pubmed
pubmed-article:1449106pubmed:articleTitleA phase I study of high-dose cisplatin, prolonged infusion 5-fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck.lld:pubmed
pubmed-article:1449106pubmed:affiliationDivision of Radiation Oncology, University of Alabama, Birmingham 35233.lld:pubmed
pubmed-article:1449106pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1449106pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1449106pubmed:publicationTypeClinical Trial, Phase Illd:pubmed